Japan's Riken Gets Initial Clearance For First Clinical Trial Of iPS Cure
This article was originally published in PharmAsia News
Executive Summary
Japan researchers working with the Riken research foundation and $1.2 billion in government funds received initial clearance for the first clinical trial of Nobel Prize-winning induced pluripotent stem cells to cure age-related macular degeneration.